{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'A PHASE 4, MULTI-CENTER, RANDOMIZED,', 'DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF', 'THE IMPACT OF APREMILAST (CC-10004) ON', 'QUALITY OF LIFE, EFFICACY, AND SAFETY IN', 'SUBJECTS WITH MANIFESTATIONS OF PLAQUE', 'PSORIASIS AND IMPAIRED QUALITY OF LIFE', 'EMBRACE', 'PROTOCOL NUMBER:', 'CC-10004-PSOR-020', 'DATE FINAL:', '26 SEP 2018', 'Amendment 1:', '17 JAN 2019', 'Amendment 2:', '01 NOV 2019', 'Amendment 3:', '01 MAY 2020', 'EudraCT NUMBER:', '2018-002850-58', 'NCT Number:', 'NCT03774875', 'IND NUMBER:', '070270', 'SPONSOR NAME / ADDRESS:', 'AMGEN, INC.', 'One Amgen Center Drive', 'Thousand Oaks, CA 91320', 'CONFIDENTIALITY NOTICE', 'This document contains confidential information of Amgen. This document', 'must not be disclosed to anyone other than the site study staff and members of', 'the institutional review board/independent ethics committee/institutional', 'scientific review board or equivalent. The information in this document cannot', 'be used for any purpose other than the evaluation or conduct of the clinical', 'investigation without the prior written consent of Amgen. If you have', 'questions regarding how this document may be used or shared, call the Amgen', 'Medical Information number: 1- - 800-77-AMGEN', 'Confidential and Proprietary', '1', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION', 'Contact Information', 'Name:', 'MD', 'Title: Senior Director, Global Development', 'Address: Amgen Inc.', 'One Amgen Center Drive', 'Thousand Oaks, CA 91320', 'Phone:', 'E-mail:', 'Note: Only call Amgen Medical Information, if you are not able to reach the Clinical Research', 'Physician(s) or Medical Monitor or designee for emergency calls.', 'Amgen Medical Information: +1-800-77-AMGEN (1-800-772-6436)', 'Confidential and Proprietary', '2', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE', '{See appended electronic signature page)', 'Signature of Celgene Therapeutic Area Head', 'dd mmm yyyy', ', MD', 'Vice President and Head of Immunology & Fibrosis Clinical Development', 'Printed Name of Celgene Therapeutic Area Head and Title', 'By my signature, I indicate I have reviewed this protocol and find its content to be', 'acceptable.', 'NOTE: Signed by Celgene based on Approval from Amgen Therapeutic Head', 'Confidential and Proprietary', '3', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE', 'Signature of Site Principal Investigator', 'dd mmm yyyy', 'Printed Name of Site Principal Investigator', 'Institution Name:', 'By my signature, I agree to personally supervise the conduct of this study at my study', 'site and to ensure its conduct is in compliance with the protocol, informed consent,', 'Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from', 'Amgen representatives, the Declaration of Helsinki, International Council for', 'Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations', 'governing the conduct of clinical studies.', 'Confidential and Proprietary', '4', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE', 'Signature of Coordinating Principal Investigator', 'dd mmm yyyy', 'Printed Name of Coordinating Principal Investigator', 'Institution Name:', 'By my signature, I agree the protocol has been written to comply with ICH Good', 'Clinical Practices guidelines and agree to offer guidance throughout the study as', 'needed.', 'Confidential and Proprietary', '5', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}